Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Adverse pregnancy outcomes increase future peripheral artery disease risk

21

Jul 2026

Adverse pregnancy outcomes increase future peripheral artery disease risk

Women who experience pregnancy complications such as gestational diabetes, preeclampsia, or preterm delivery have a significantly increased long-term risk of developing peripheral artery disease (PAD) later in life, according to a new study published July 21st in the open access journal PLOS Medicine by Casey Crump of the University of Texas, US, and colleagues.

AI-powered PeptiVerse could accelerate peptide drug discovery

21

Jul 2026

AI-powered PeptiVerse could accelerate peptide drug discovery

Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, the strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 drugs, the widely used weight-loss treatments.

Moderate coffee intake may support heart health, AHA says

21

Jul 2026

Moderate coffee intake may support heart health, AHA says

The American Heart Association finds that habitual coffee consumption is associated with lower risks of several cardiovascular outcomes, although most evidence comes from observational studies. Moderate intake is generally safe for most adults, while energy drinks and individual caffeine sensitivity may increase cardiovascular concerns.

Childhood ultra-processed food intake associates with altered insulin responses

21

Jul 2026

Childhood ultra-processed food intake associates with altered insulin responses

Researchers analyzed dietary and metabolic data from 508 nondiabetic Mexican American children in the SAFARI family cohort, finding that higher ultra-processed food scores were associated with lower insulin sensitivity and altered early insulin secretion measures. The exploratory cross-sectional study did not establish causality, and its multiple comparisons, historical dietary data, and questionnaire-based UPF estimates warrant confirmation in longitudinal studies and trials.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.